{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.54 vs. cons $0.53",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Net Sales",
      "prediction": "BEAT",
      "answer": "pred ~$7.15B vs. cons $7.05B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "US Coffee segment operating income growth (margin recovery)",
      "prediction": "BEAT",
      "answer": "pred ~-8% vs. cons ~-15% decline",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS growth (constant currency)",
      "prediction": "UNCHANGED",
      "answer": "guide ~11% cc growth vs. cons ~11% cc growth (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Net Sales range",
      "prediction": "UNCHANGED",
      "answer": "guide ~$26.1B midpoint vs. cons ~$26.2B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 EPS growth phasing (H2 acceleration commentary)",
      "prediction": "BETTER",
      "answer": "guide ~high-teens % growth vs. cons ~15% growth (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.3,
  "day5_path": "FADE",
  "day5_rationale": "A modest EPS/sales beat with reaffirmed FY guidance likely produces an initial relief pop (stock already re-rated from ~$27 to ~$31 into the print on the Barclays upgrade and coffee-easing narrative, so much of the good news is pre-priced). Over the following days, below-the-line items (convertible preferred cost, ~$190M NCI from the Coffee JV) and lingering execution risk (vacant Global Coffee Co. CEO seat, H2-weighted margin recovery) give analysts room to trim out-period (H2/FY) EPS even after an in-line-to-slight beat, causing the initial pop to fade rather than extend.",
  "day5_confidence": "LOW"
}